WHO alerts unregulated supply of Falsified (contaminated) Oxymorphone Hydrochloride 40mg

This WHO Medical Product Alert refers to one batch of falsified Oxymorphone Hydrochloride 40mg. The falsified product was detected in the unregulated supply chain in Finland and reported to WHO in July 2024 by the Finnish Medicines Agency (FIMEA). 

Oxymorphone Hydrochloride is a semi-synthetic opioid used to treat moderate to severe pain. However, laboratory analysis of samples of the falsified product found that the tablets contained metonitazene instead.

Metonitazene is a potent psychoactive synthetic opioid drug, with no officially recognised or authorised medicinal or therapeutic use. It is under international control as a Schedule I narcotic drug following recommendations of the WHO Expert Committee on Drug Dependence in 2021. Small doses can result in serious adverse effects such as respiratory depression, severe sedation, and addiction, and an overdose may be fatal.

How to identify this falsified product

This product is confirmed as falsified because it deliberately misrepresents its identity, composition, and source.

The falsified product imitates Oxymorphone Hydrochloride marketed by Aurolife Pharma., who have confirmed that the product, subject of this Alert, is falsified and was not produced by their company.

To identify this falsified product check for the following:

• The falsified version label does not have a barcode on the bottle.
• The falsified version is labelled 40mg. Aurolife Pharma Oxymorphone Hydrochloride is only available in 5mg and 10mg doses.
• The falsified versions of the tablets lack embossed letters/numbers.
• The falsified product’s label is missing the National Drug Code of the United States of America.

Advice to healthcare professionals and regulatory authorities 

All medical products must be obtained from authorised/licensed suppliers. Healthcare professionals should report any incident of adverse effects, lack of expected effects or suspected falsification to the National Regulatory Authorities/National Pharmacovigilance Centre.

WHO advises increased surveillance and diligence within the supply chains of countries and regions likely to be affected by these falsified products. Increased surveillance of the informal/unregulated market is also advised. National regulatory authorities/health authorities/law enforcement are advised to immediately notify WHO if the falsified product is detected in their country. 

Edits made by EP News Bureau